Arkema's Stock Jumps 8.8% and Returns to Its August 2025 Level
Arkema's stock recorded a significant increase of 8.81% this Tuesday, February 10, 2026, reaching 64.20 euros. The specialty chemicals company's stock thus achieved a new annual high at 59.30 euros, surpassing the previous record set the day before. This bullish momentum is part of a strong rebound that began a week ago, with a gain of nearly 25% over seven days.
Strategic Recommendation Change Fuels Rally
The spectacular rebound of the stock is notably supported by a change in strategic recommendation from Goldman Sachs published this Tuesday. The American investment bank has shifted its opinion from neutral to buy, while significantly raising its price target from 51 euros to 71 euros. This new target gives the French chemist an additional appreciation potential of about 10.6% compared to the current trading level. This improvement in perspective comes as the group, specialized in advanced materials and specialty chemical solutions, goes through a phase of stock market revaluation. Goldman Sachs' turnaround reflects a more optimistic view of the group's fundamentals and its ability to generate value in a sector environment that remains mixed.
Technical Parameters Indicate Market Tension
An examination of technical parameters reveals significant tension on Arkema following this surge. The Relative Strength Index (RSI) now reaches 83, a level well above the 70 threshold that traditionally signals an overbought zone. This situation indicates the intensity of demand for the stock in recent sessions. Moreover, the price has now significantly detached from its reference moving averages. The quote now exceeds its 50-day moving average by 23%, positioned at 52.14 euros, and its 200-day average by 11.8%, established at 57.44 euros. This configuration illustrates the acceleration of the recent bullish movement. The next technical resistance threshold is at 65.85 euros, a level now close after today's push. Despite this short-term dynamism, the annual performance of the stock remains negative at -20.05%, highlighting the difficulties encountered by the group over the past twelve months.
